(813) 971-8080

7210 Wareham Drive, Tampa, FL 33647

weight loss forecasts

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion

News /

March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss […]

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down

News /

March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »

Recession Is Coming – But Commercial Diet Companies Could Benefit

News /

March 13, 2025 Marketdata, the parent company of DietBusinessWatch.com, has updated its report on the Commercial & Retail Weight Loss Market. Several things have become apparent as we do the research Marketdata analysts see a possible opportunity this year for the commercial (non-medical) weight loss firms to recover some ground. Here’s how we think 2025

Recession Is Coming – But Commercial Diet Companies Could Benefit Read More »

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report

News /

Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »

GLP-1 Drugs Market Update

News /

Sept. 23, 2024 According to Becker’s Hospital Review… On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic.  The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The

GLP-1 Drugs Market Update Read More »

Medifast To Launch National Marketing Campaign

News /

May 20, 2024 Medifast today announced the launch of the first phase of its multimillion-dollar national marketing campaign. The campaign will highlight OPTAVIA’s new offering in collaboration with LifeMD®, the GLP-1 Lifestyle Program. View the full release here: https://www.businesswire.com/news/home/20240520770526/en/ This will be an investment of up to $30 million in company-led marketing efforts. Medifast is committed

Medifast To Launch National Marketing Campaign Read More »

Telehealth Weight Loss Market Worth $6.9 Billion And Growing

News /

April 13, 2024 Marketdata LLC (parent company of DietBusinessWatch) has just released new research, a report entitled: “The Telehealth Weight Loss Market”. The market for weight loss programs delivered via telehealth / telemedicine companies is worth $6.9 billion, and growing. Telehealth soared during the pandemic in 2020 as consumers stayed home and communicated with their

Telehealth Weight Loss Market Worth $6.9 Billion And Growing Read More »

Scroll to Top